Turkey: Inofab Health, the Turkish Healthtech startup has secured a new $1M funding round, from Re-Pie Asset Management Co, Teknoloji Yatırım, and F+ Ventures.
Inofab Health helps patients and enthusiasts of respiratory health to better understand, track, and proactively manage their lung health using a powerful digital health platform. The Spirohome spirometers product provides clinical-grade accuracy with each test, and the app makes spirometry clear, quick, and convenient for all users, the startup states.
SpiroCloud is a web-based portal that empowers communication between healthcare professionals and patients. This year, they will present two new products to the market: SpiroClinic – a respiratory diagnosis device to be used in clinical settings, and SpiroHaler – a smart inhaler attachment to monitor the medication use in spirometers.
Amidst the pandemic, Inofab Health noted remote patient monitoring in respiratory care as an essential need, and with the news funds, aim to meet the needs in remote respiratory care by adding new products to their existing portfolio.
Their products are available to users in 50 countries, with sales partners and distributors in 15 different countries. Inofab Health is looking to continue developing sustainable business models in the respiratory domain to address the needs of different local markets.
The startup is planning to present its solutions in North America by the end of this year to become a worldwide player in the respiratory domain.